|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Proteome identification of binding-partners interacting with cell polarity protein Par3 in Jurkat cells显示文摘evolutionarily 保存的房间极性蛋白质 Par3,像支架的 PDZreontaining 蛋白质,在上皮的房间极性的建立和维护起一个关键作用。尽管在在上皮的房间建立房间极性的 Par3 的角色强烈地被探索了,在造血的房间的 Par3 的功能留下逃犯。处理这个问题,我们产生了 Par3 PDZ 领域的 GST 熔化蛋白质。由把 GST-pull-down 途径与液体层析双人脚踏车团 spectrometry 相结合,我们在 Jurkat 房间(一根 T 房间线) 识别了 Par3 的 PDZ 领域的 10 潜在的新奇有约束力的蛋白质。有三蛋白质的 Par3 的相互作用—原子运输蛋白质 importin-α4 和 proteasome 使活跃之物 PA28β 和 PA28γ—被证实在 vitro 绑定试金, co-immunoprecipitation 试金和免疫荧光显微镜学使用。我们的结果有潜力揭开在血房间的房间极性蛋白质 Par3 的新奇功能。 | Ying Zhou Longhou Fang Dan Du Wenchao Zhou Xiujing Feng Jiwu Chen Zhe Zhang Zhengjun Chen | 2008 | Acta Biochimica et Biophysica Sinica2008，40，8： | 2 |
| 2 | Modeling and solution based on stochastic games for development of COA under uncertainty显示文摘Developing a course of action(COA) is a key step in military planning. In most extant studies on the COA development,only the unilateral actions of friendly forces are considered. Based on stochastic games, we propose models that could deal with the complexities and uncertainties of wars. By analyzing the equilibrium state of both opponent sides, outcomes preferable to one side could be achieved by adopting the methods obtained from the proposed models. This research could help decision makers take the right COA in a state of uncertainty. | CHEN Chao DU Zhengjun LIANG Xingxing SHI Jianmai ZHANG Hao | 2019 | Journal of Systems Engineering and Electronics2019，30，2： | 2 |
| 3 | Cell polarity protein Par3 complexes with DNA-PK via Ku70 and regulates DNA double-strand break repair显示文摘分区有缺陷者 3 (Par3 ) ,在 conservedPar3/Par6/aPKC 建筑群的一个关键部件,在房间极性的戏基础角色。此处,我们报导 Ku70 和通过试管内绑定试金的蛋白质由液体层析双人脚踏车质谱法跟随了的 Ku80 同样新奇的交往 Par3 的鉴定。Ku70/Ku80 蛋白质是 DNA 依赖的蛋白激酶(DNA-PK ) 的二个关键规章的子单元,它在修理双海滨脱氧核糖核酸裂缝(DSB ) 起一个必要作用。我们决定 Par3 withKu70/Ku80 的原子协会被 y 照耀(红外) 提高,有势力 DSB inducer。而且, DNA-PKcs, DNA-PK 的催化子单元,响应红外与 Par3/Ku70/Ku80 建筑群交往了。Par3over 表示或击倒分别地能够 up- 或 downregulat-ing DNA-PK 活动。而且, Par3 击倒的房间被发现在随机的原生质标志集成有缺点,在 DSB 修理追随者红外有缺点、对射线敏感,类似于 Ku70knockdown 房间的显型。这些调查结果作为 DNA-PK 建筑群的一个新奇部件识别 Par3 并且含有到 DSB 修理的房间极性的一个意外连接。 | Longhou Fang YiGuo Wang Dan Du Guang Yang Tim Tak Kwok Siu Kai Kong Benjamin Chen David J Chen Zhengjun Chen | 2007 | Cell Research2007，17，2： | 2 |
| 4 | Use of satellite imagery to assess the trophic state of Miyun Reservor,Beijing,China显示文摘 | WANG Zhengjun HONG Jianming DU Guisen | | 0，，： | 1 |
| 5 | Intraoperative device closure of secundum atrial septal defect with a right anterior minithoracotomy in 100 patients显示文摘 | Li Hongxin Guo Wenbin Sheng Lijun Wang Zhengjun Liang Hao Zou Chengwei Du Liang Yuan Guidao | 2007 | The Journal of Thoracic and Cardiovascular Surgery2007，，4： | 1 |
| 6 | A Case Report:Severe Bullous Skin Reaction Induced by Anti-PD-1 Antibody(Toripalimab)Therapy in a Patient with Thymic Carcinoma显示文摘The development of immune checkpoint inhibitors,such as those targeting programmed cell death protein 1(PD-1),represents a major breakthrough in cancer therapy.Although immune checkpoint blockade therapy has a favorable risk/benefit ratio,it causes significant immune-related adverse events(irAEs),such as cutaneous reactions,in particular,severe bullous skin reactions and toxic epidermal necrolysis.Here,we report a case of a 51-year-old woman with malignant thymoma who developed a severe bullous skin reaction(characterized by a systemic rash,bullae,epidermal desquamation,and Stevens-Johnson syndrome)as a result of treatment with the PD-1 inhibitor toripalimab.The patient was treated with high doses of glucocorticoid,intravenous immunoglobulin,and intensive care,and eventually recovered from the severe irAEs.The intravenous injection of anti-PD-1 antibodies induces cutaneous reactions,which are associated with higher mortality rates.High doses of glucocorticoid combined with intravenous immunoglobulin are effective in alleviating such irAEs.Thus,improving the level of care and preventing skin infections can effectively reduce the risk of death. | Chong TENG Xiaowei SONG Chengjuan FAN Yashuang ZHAO Lina DU Siqi MAN Yuanyuan HU Zhengjun JIANG Tao XIN | 2022 | Clinical Cancer Bulletin2022，1，3： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员